
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
, ,
“Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: an analysis of UK electronic medical records”, Semin Arthritis Rheum, 2019.
, , , “ACL and meniscal injuries increase the risk of primary total knee replacement for osteoarthritis: a matched case-control study using the Clinical Practice Research Datalink (CPRD)”, Br J Sports Med, 2018.
, “Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis”, Semin Arthritis Rheum, vol. 47, pp. 605-610, 2018.
, , “Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study”, J Bone Miner Res, vol. 32, pp. 203-211, 2017.
, “The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study”, Lancet, vol. 389, pp. 1424-1430, 2017.
, “Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients”, Alzheimers Dement (N Y), vol. 3, pp. 612-621, 2017.
, “Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis”, J Bone Miner Res, vol. 31, pp. 2008-2015, 2016.
, “Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom”, Rheumatology (Oxford), vol. 54, pp. 2244-8, 2015.
, “Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical Practice Research Datalink”, Osteoarthritis Cartilage, vol. 23, pp. 594-600, 2015.
, “Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study”, Ann Rheum Dis, vol. 74, pp. 557-63, 2015.
, “The effect of body mass index on the risk of post-operative complications during the 6 months following total hip replacement or total knee replacement surgery”, Osteoarthritis Cartilage, vol. 22, pp. 918-27, 2014.
, ,
“The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database”, Osteoarthritis Cartilage, vol. 20, pp. 519-24, 2012.
, , “Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study”, Bmj, vol. 343, p. d7222, 2011.
, “Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study”, Ann Rheum Dis, vol. 70, pp. 134-8, 2011.
, “The effect of hip and knee arthroplasty on oral anti-inflammatory use and the relationship to body mass index: results from the UK general practice research database”, Osteoarthritis Cartilage, vol. 19, pp. 29-36, 2011.
, “Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use”, Arthritis Rheum, vol. 63, pp. 992-1001, 2011.
, “Temporal trends in hip and knee replacement in the United Kingdom: 1991 to 2006”, J Bone Joint Surg Br, vol. 92, pp. 130-5, 2010.
, “The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 57, pp. 1151-7, 2007.
, “The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database”, Rheumatology (Oxford), vol. 44, pp. 1394-8, 2005.
,